November 18, 2025 — Leads & Copy —
RespireRx Pharmaceuticals Inc. (RSPI) announced that the Securities and Exchange Commission (SEC) has revoked the registration of its securities, effective November 14, 2025. The revocation comes as a result of an order issued by the SEC on November 13, 2025, following administrative proceedings initiated on September 11, 2025.
The SEC stated it was necessary and appropriate for the protection of investors to accept the settlement offer submitted by RespireRx. The findings were based on unsolicited quotations of RSPI’s common stock on the Expert Market of the OTC Link ATS, and RSPI’s failure to file periodic reports with the Commission since the Form 10-Q for the period ended September 30, 2023.
The Commission ordered the revocation of registration for each class of RespireRx Pharmaceuticals Inc.’s securities registered under Section 12 of the Exchange Act, effective November 14, 2025.
RSPI made the settlement offer on September 30, 2025, and was awaiting a determination as to whether its offer would be accepted. The government shutdown, effective October 1, 2025, and reopened on November 12, 2025, with the Commission releasing the acceptance of the settlement on November 13, 2025. The company stated there is no monetary fine.
The registration of RespireRx’s common stock, the only class of securities previously registered, has been revoked.
The company plans to re-register its common stock, and possibly other classes of its stock, on Form 10 in the future, requiring the filing of two years of audited financial statements. RSPI currently believes that it would be most efficient to wait until after December 31, 2025, and file Form 10 with December 31, 2024, and December 31, 2025 audited financial statements. A filed Form 10 under Section 12(g) becomes automatically effective sixty (60) days after filing, and RSPI believes that from the effective date forward, it would need to remain current with the required periodic filings without having to file any of the previously required but unfiled periodic filings.
RespireRx Pharmaceuticals Inc. and its subsidiaries, EndeavourRx LLC and ResolutionRx Ltd, collectively, the RespireRx Group, is discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (ADHD), recovery from SCI, certain neurological orphan diseases and obstructive sleep apnea (OSA).
The RespireRx Group is developing a pipeline of new and repurposed drug products based on its broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively that make up EndeavourRx LLC, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors that make up ResolutionRx Ltd. Certain therapeutic opportunities have been retained at RespireRx.
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx LLC will continue RespireRx’s focus on its AMPAkines programs.
Under an Amended and Restated Patent License Agreement entered into as of October 27, 2025 with the University of Wisconsin-Milwaukee Research Foundation, Inc. and on behalf of its EndeavourRx LLC subsidiary, RespireRx has in-licensed rights to certain selectively acting GABAkines. EndeavourRx LLC will continue RespireRx’s focus on developing KRM-II-81 for the treatment of epilepsy and pain.
On September 23, 2025, RespireRx received a Notice of Award from the National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), award number 1R44NS143576, under the Small Business Innovation Research (SBIR) program. The amount of the award is $1,499,869 for the budget period September 23, 2025 through August 31, 2026. The total amount requested in the application was $2,999,738 over the two-year period. The purpose of the project is to complete the required preclinical toxicology and other related efforts to support the filing of an investigational new drug application (IND) to study in clinical trials, its lead GABAkine, KRM-II-81 for the treatment of epilepsy.
ResolutionRx Ltd (Australian Company Number a/k/a ACN 664 925 651) was formed in Australia on January 11, 2023 by RespireRx as an unlisted public company. RespireRx has contributed by sublicense and license with ResolutionRx, its obstructive sleep apnea drug development program subject to certain liabilities. ResolutionRx now engages in the research and development (R&D) associated with that program, initially for the development of a new formulation of dronabinol for use in an anticipated pharmacokinetic and pharmacodynamic study of the lead new formulation to be followed by a Phase 3 clinical trial and the filing of regulatory approval for the treatment of OSA. Dronabinol, an endocannabinoid receptor agonist, has already demonstrated significant improvement in the symptoms of OSA in two Phase 2 clinical trials.
Jeff Margolis
Senior Vice President, Chief Financial Officer, Treasurer and Secretary
RespireRx Pharmaceuticals Inc.
U.S. Telephone: 917-834-7206
Email:
jmargolis@respirerx.com
Source: RespireRx Pharmaceuticals Inc.
